Standard, Complementary, and Future Treatment Options for Tics
- 10 Downloads
Purpose of Review
Tics occur in up to 20% of children and are a defining feature of Tourette syndrome (TS). When treatment is necessary, there are many options available. The purpose of this review is to present an overview of the standard, complementary/alternative medicine (CAM), and emerging treatments of tics and provide examples of the current evidence supporting these therapies.
Behavioral therapy and conventional pharmacotherapy are the mainstays of treatment and have the strongest evidence to support their use. CAM is common, but there are few rigorous randomized, controlled trials evaluating the safety and efficacy of these modalities. Several novel pharmacological and nonpharmacological treatments targeting specific pathways thought to be involved in TS are currently being studied with the hope of expanding future treatment options.
We conclude that there is an ongoing need for new evidence-based approaches for safe and effective treatment of tics.
KeywordsTics Tourette syndrome Placebo effect Complementary/alternative medicine CAM
Compliance with Ethical Standards
Conflict of Interest
April N. Sharp reports no conflict of interest.
Harvey S. Singer reports grants from Tourette Association of America.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 10.•• Thenganatt MA, Jankovic J. Recent advances in understanding and managing tourette syndrome. F1000Res. 2016 5. Pii: F1000 faculty Rev-152. This article details current understanding of pathophysiology of TS and targeted therapies. Google Scholar
- 13.•• Whittington C, Pennant M, Kendall T, Glazebrook C, Trayner P, Groom M, et al. Practitioner review: treatments for tourette syndrome in children and young people—a systematic review. J Child Psychol Psychiatry. 2016;57(9):988–1004. This is a systematic review comparing the evidence for standard treatments of TS. CrossRefPubMedGoogle Scholar
- 24.Gupta S, Somkuwar S, Garg G. Clerodendron inerme: an update of its indigenous uses, phytochemistry and pharmacology. Int J Chem Sci. 2010;8(1):203–12.Google Scholar
- 26.Chen HL, Lee HJ, Huang WJ, Chou JF, Fan PC, Du JC, et al. Clerodendrum inerme leaf extract alleviates animal behaviors, Hyperlocomotion, and Prepulse inhibition disruptions, mimicking Tourette syndrome and schizophrenia. Evid Based Complement Alternat Med. 2012;2012:284301.PubMedPubMedCentralGoogle Scholar
- 34.Hampson M, Scheinost D, Qiu M, Bhawnani J, Lacadie CM, Leckman JF, et al. Biofeedback of real-time functional magnetic resonance imaging data from the supplementary motor area reduces functional connectivity to subcortical regions. Brain Connect. 2011;1(1):91–8.CrossRefPubMedPubMedCentralGoogle Scholar
- 42.•• Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, et al. Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. JAMA. 2015;313(24):2456–73. This is a systematic review of the benefits and risks of cannabinoids as medical treatment, including for TS. CrossRefPubMedGoogle Scholar
- 44.Curtis A, Clarke CE, Rickards HE. Cannabinoids for Tourette's syndrome. Cochrane Database Syst Rev. 2009;4:CD006565.Google Scholar
- 56.• Budman E, Deeb W, Martinez-Ramirez D, Pilitsis JG, Peng-Chen Z, Okun MS, Ramirez-Zamora A. Potential indications for deep brain stimulation in neurological disorders: an evolving field. Eur J Neurol. 2017 20. https://doi.org/10.1111/ene.13548. This is a thorough review of the current evidence for use of DBS in several neurological conditions.
- 58.•• Martinez-Ramirez D, Jimenez-Shahed J, Leckman JF, Porta M, Servello D, Meng FG, Kuhn J, Huys D, Baldermann JC, Foltynie T, Hariz MI, Joyce EM, Zrinzo L, Kefalopoulou Z, Silburn P, Coyne T, Mogilner AY, Pourfar MH, Khandhar SM, Auyeung M, Ostrem JL, Visser-Vandewalle V, Welter ML, Mallet L, Karachi C, Houeto JL, Klassen BT, Ackermans L, Kaido T, Temel Y, Gross RE, Walker HC, Lozano AM, Walter BL, Mari Z, Anderson WS, Changizi BK, Moro E, Zauber SE, Schrock LE, Zhang JG, Hu W, Rizer K, Monari EH, Foote KD, Malaty IA, Deeb W, Gunduz A, Okun MS. Efficacy and Safety of Deep Brain Stimulation in Tourette Syndrome. JAMA Neurol. https://doi.org/10.1001/jamaneurol.2017.4317. This study provides efficacy and safety data for a large cohort of TS patients who underwent DBS.
- 59.• Schrock LE, Mink JW, Woods DW, Porta M, Servello D, Visser-Vandewalle V, et al. Tourette syndrome deep brain stimulation: a review and updated recommendations. Mov Disord. 2015;30(4):448–71. This article provides recommendations when to consider use of DBS as treatment for TS. CrossRefPubMedGoogle Scholar